Dynavax Technologies | Betriebsaufwand



Operating Expenses Veränderung Datum
AbbVie USD 9.61B 6.98B 2025-03
Adma Biologics USD 80.47M 268K 2024-12
Amgen USD 6.78B 401M 2024-12
AstraZeneca USD 9.91B 2.94B 2025-03
Biogen USD 2.01B 13.3M 2024-12
BioMarin Pharmaceutical USD 585.91M 45.94M 2024-12
Bristol-Myers Squibb USD 8.23B 3.32B 2025-03
Dynavax Technologies USD 73.66M 3.12M 2024-12
Gilead Sciences USD 4.43B 687M 2025-03
Glaxosmithkline GBP 7.42B 408M 2024-12
Merck USD 9.66B 1.67B 2025-03
Neurocrine Biosciences USD 485.7M 47.4M 2024-12
Novartis USD 11.28B 1.73B 2024-12
Pfizer USD 10.05B 8.12B 2025-03
Regeneron Pharmaceuticals USD 2.44B 362M 2025-03
Roche Holding CHF 11.43B 1.48B 2024-12
Sarepta Therapeutics USD 496.73M 51.76M 2024-12
TG Therapeutics USD 78.24M 6.79M 2024-12
Vertex Pharmaceuticals USD 1.89B 230.4M 2024-12



Dynavax Technologies Betriebsaufwand - Diese Werte, historische Daten, Prognosen, Statistiken, Diagramme und ökonomische Kalender - May 2025.